| Name | Sofalcone |
| Description | Sofalcone (SU-88), a gastric antiulcer agent in clinical use, is known to induce the expression of Heme oxygenase-1 (HO-1) in gastric epithelium. |
| Cell Research | Primary HUVECs are seeded at 60?000 cells per well and incubated at 37°C for 14 to 16 hours to allow tube formation. Cells are then cultured in the presence of either TNF-α (10 ng/mL) alone, with both TNF-α (10 ng/mL) and Sofalcone 50 μM, or control media for 8 to 12 hours. Tube formation is assessed, and images are captured using microscope at ×4 magnification. |
| In vitro | Sofalcone (50 μmol/L) significantly enhances HO-1 mRNA and protein expression in both trophoblasts and primary human umbilical vein endothelial cells (HUVECs), evidenced by Western blot analyses and comparison with control groups (P<0.05). It also boosts Nrf2 presence in HUVEC nuclear fractions after 6 hours and upregulates NQO1, TXN, and GCLC expression in primary HUVECs dose-dependently over 24 hours. Additionally, Sofalcone markedly reduces sFlt-1 concentrations in culture media and decreases THP-1 monocyte adherence to HUVECs in a dose-dependent manner, underscoring its potential therapeutic implications for vascular health. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | DMSO : 50 mg/mL (110.98 mM)
|
| Keywords | inhibit | Sofalcone | Bacterial | SU88 | SU 88 | Inhibitor | Autophagy |
| Inhibitors Related | Neomycin sulfate | Stavudine | Ampicillin sodium | Kanamycin sulfate | Sulfamethoxazole sodium | Hydroxychloroquine | Guanidine hydrochloride | Doxycycline | Paeonol | Naringin | Dimethyl sulfoxide | Salicylic acid |
| Related Compound Libraries | Bioactive Compound Library | Drug Repurposing Compound Library | Anti-Cancer Approved Drug Library | Anti-Aging Compound Library | Bioactive Compounds Library Max | Anti-Cancer Drug Library |
United States
